Group 1 - The company, Longquan Co., Ltd. (002671.SZ), stated on the investor interaction platform that it is currently not engaged in any wind power tower business [1]

（文章来源：每日经济新闻） 每经AI快讯，有投资者在投资者互动平台提问：公司混凝土预制塔筒有何竞争壁垒？这个前景如何？ 龙泉股份（002671.SZ）12月5日在投资者互动平台表示，目前，公司没有承接风电混凝土预制塔筒相关 业务。 ...

Group 1 - The company Longquan Co., Ltd. announced that its wholly-owned subsidiary, Wuxi Xinfeng Pipe Industry Co., Ltd., has signed contracts with China General Nuclear Power Engineering Co., Ltd. for the supply of alloy steel and chromium-controlled steel pipe fittings for two projects [2] - The total contract value, including tax, amounts to approximately RMB 50,756,655.58 (about 50.76 million) [2]

Group 1 - China Pacific Insurance has received approval from the financial regulatory authority for Wang Yuhua to serve as a director [1] - Shanghai Bank announced that the regulatory authority has approved Chen Lei's qualification as vice president [2] - Shanghai HuGong has decided to terminate the "Aerospace Equipment Manufacturing Base" fundraising project due to significant changes in project feasibility [3] Group 2 - Dongwang Times plans to reduce its stake by up to 1.20% through share sales [4] - Zhinancun intends to increase its capital by 100 million yuan in its wholly-owned subsidiary, Maigao Securities [5] - Jinxinnong reported a sales revenue of 115 million yuan from pig sales in November [6] Group 3 - Tiantan Biological has completed the Phase III clinical trial of its human prothrombin complex, showing good efficacy and safety for hemophilia B patients [7] - Beijete's subsidiary has signed a framework agreement for equity acquisition to gain control of Yunnan Wenye Nonferrous Metals [8] - Zhongsheng Pharmaceutical's RAY1225 injection has received approval for a new clinical trial indication for treating metabolic-associated fatty liver disease [9] Group 4 - Enhua Pharmaceutical's hydrochloride sulpiride tablets have passed the consistency evaluation for generic drugs [10] - Shenkong Co. plans to invest 60 million yuan in a semiconductor industry fund [11] - Lianhuan Pharmaceutical's subsidiary has received approval for its drug to pass the consistency evaluation for generic drugs [12] Group 5 - Dazhong Transportation has received approval to issue debt financing tools totaling 4.5 billion yuan [13] - Jintian Titanium Industry plans to invest 50 million yuan in an industry merger and acquisition fund [14] - Changchun Gas has committed over 1.7 billion yuan to gas facility upgrades [15] Group 6 - Laimei Pharmaceutical's innovative anti-cancer drug "Nano Carbon Iron" has received approval for clinical trials [16] - Longquan Co. has signed supply contracts worth approximately 50.76 million yuan for nuclear power components [17] - Igor plans to distribute a cash dividend of 1 yuan per 10 shares [18] Group 7 - Xingfa Group's subsidiary has signed a processing agreement for 80,000 tons of lithium iron phosphate [20] - Yunjigroup's director Wang Wanfeng has resigned for personal reasons [21] - Saiseng Pharmaceutical's application for the listing of a new drug has been accepted by the regulatory authority [22] Group 8 - Xinhua Medical has obtained registration certificates for two new medical devices [23] - Chaoying Electronics plans to invest 100 million USD in its Thai subsidiary for an AI circuit board expansion project [24] - Suzhou Planning's application to acquire 100% of Dongjin Aviation has been accepted by the Shenzhen Stock Exchange [25]

Core Viewpoint - Longquan Co., Ltd. has announced that its wholly-owned subsidiary, Wuxi Xinfeng Pipe Industry Co., Ltd., has signed supply contracts with China General Nuclear Power Engineering Co., Ltd. for the Fangchenggang Project and the Taishan Project, totaling approximately 50.76 million yuan, which accounts for about 4.43% of the company's audited revenue for the fiscal year 2024 [1] Group 1 - The contracts include the supply of alloy steel and controlled chromium steel pipe fittings for the Fangchenggang Project Units 5 and 6, as well as for the Taishan Project Units 3 and 4 [1] - The total contract value is approximately 50.76 million yuan [1] - The contract value represents about 4.43% of the company's audited revenue for the year 2024 [1]

证券代码：002671 证券简称：龙泉股份 公告编号：2025-082 山东龙泉管业股份有限公司 关于全资子公司签订合同的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 特别提示： 3、合同履行过程中，如果发生设计变更或遇到自然灾害等不可预计的或不可抗力等因 素的影响，存在合同无法全部履行或延缓履行的风险。 山东龙泉管业股份有限公司（以下简称"公司"）分别于 2025 年 10 月 9 日 及 2025 年 11 月 8 日 在 《 中 国 证 券 报 》 《 证 券 时 报 》 和 巨 潮 资 讯 网 （http://www.cninfo.com.cn）上披露了《关于全资子公司项目中标公示的提示性 公告》（公告编号：2025-068）《关于全资子公司项目中标的公告》（公告编号： 2025-080）。 近日，公司之全资子公司无锡市新峰管业有限公司（以下简称"新峰管业"） 收到与中广核工程有限公司签订的《防城港项目 5、6 号机组 LOT44Ae 常规岛合 金钢及控铬钢管管件供应合同》《台山项目 3、4 号机组 LOT44Ae 常规岛合金钢 及控铬钢管管件 ...

Core Viewpoint - Longquan Co., Ltd. announced that its wholly-owned subsidiary, Xinfeng Pipe Industry, signed supply contracts with China General Nuclear Power Engineering Co., Ltd. for the Fangchenggang Project and the Taishan Project, with a total contract value of RMB 50.7567 million [1] Group 1 - The contracts include the supply of alloy steel and chromium-controlled steel pipe fittings for the Fangchenggang Project Units 5 and 6, and Taishan Project Units 3 and 4 [1] - The contract is structured as a "framework + order" model, with a planned delivery period extending to 2027 [1] - The total contract value represents approximately 4.43% of the company's audited revenue for the fiscal year 2024, indicating a positive impact on the company's revenue and operating profit [1]

Core Viewpoint - Longquan Co., Ltd. announced significant contracts won by its wholly-owned subsidiary, Wuxi Xinfeng Pipe Industry Co., Ltd., which are expected to positively impact the company's revenue and profit during the supply period [1] Group 1: Contract Details - The contracts signed include the supply of alloy steel and chromium-controlled steel pipe fittings for the Fangchenggang Project Units 5 and 6, and the Taishan Project Units 3 and 4 [1] - The total contract value amounts to approximately RMB 50,756,655.58, which represents about 4.43% of the company's audited revenue for the fiscal year 2024 [1] Group 2: Financial Impact - The execution of these contracts is anticipated to have a positive effect on the company's operating revenue and operating profit during the supply period [1]

（文章来源：证券日报） 证券日报网讯 12月2日，龙泉股份在互动平台回答投资者提问时表示，截至2025年11月28日，公司股东 人数为23300户。 ...

证券日报网讯龙泉股份11月21日在互动平台回答投资者提问时表示，截至2025年11月20日，公司股东人 数为23，899户。 （文章来源：证券日报） ...